PLL Therapeutics

Founded in 2019, PLL Therapeutics, a biopharmaceutical company developing a groundbreaking polypeptide delivery platform, is spearheading a unique early-diagnostics and therapeutic approach for treating the root cause of auto-immune and neurodegenerative diseases. PLL focuses on restoring gut integrity. Its initial indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. The company’s therapy, PLL001, consists of several API molecules that, when combined, can heal a leaky gut. PLL’s ‘polytargeted’ drug therapy aims at destroying the initialization of the disease by combatting, within the gut, the multiple external and internal factors that drive the onset of ALS, while facilitating the development of cells in the microbiota to rebuild the gut barrier. PLL’s approach for restoring the microbiome derives from its patented poly-L-lysine technology, an effective drug carrier able to transport several molecules and release the drug at ‘point of use’ without side effects. The platform will play a key role in the early detection of auto-immune and neurogenerative diseases (ALS) and proliferative disorders (colon cancer) through specific biomarkers. PLL Therapeutics is led by a highly experienced management team. A Phase I clinical trial is underway, with a Phase IIB planned for 2025. The company is located near Bordeaux, France.